Related Experiment Videos
Updates on the multimodality management of desmoplastic small round cell tumor
Ashwin A Kallianpur1, Nootan K Shukla, Suryanarayan V S Deo
1Department of Surgical Oncology, All India Institute of Medical Science, New Delhi, India. docash04@yahoo.com
Abstract:
Desmoplastic Small Round Cell Tumor (DSRCT) is a rare and an aggressive malignancy with poor outcome. This tumor can co-express epithelial, neural, and mesenchymal markers. The molecular hallmark of DSRCT is the EWS-WT1 fusion protein. Despite the diversities in treatment modality, the best results have been seen with radical surgery and adjuvant or neoadjuvant chemotherapy.
Insights
Desmoplastic Small Round Cell Tumor (DSRCT) is a rare, aggressive cancer. The EWS-WT1 fusion protein is its hallmark, and radical surgery with chemotherapy offers the best outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pathology
Background:
- Desmoplastic Small Round Cell Tumor (DSRCT) is a rare and aggressive malignancy.
- It presents with a poor prognosis and can exhibit diverse cellular marker expression.
- The defining molecular characteristic is the EWS-WT1 fusion protein.
Purpose of the Study:
- To summarize the key features of Desmoplastic Small Round Cell Tumor.
- To highlight the diagnostic and prognostic indicators.
- To review current treatment outcomes.
Main Methods:
- Literature review of DSRCT cases.
- Analysis of molecular markers, particularly EWS-WT1 fusion.
- Evaluation of treatment modalities and outcomes.
Main Results:
- DSRCT is characterized by co-expression of epithelial, neural, and mesenchymal markers.
- The EWS-WT1 fusion protein is the specific molecular hallmark.
- Combined modality treatments, including surgery and chemotherapy, show the best results.
Conclusions:
- DSRCT requires a multidisciplinary approach for management.
- Early diagnosis and aggressive treatment are crucial for improving patient outcomes.
- Further research into targeted therapies is warranted.